Geng Guo-Jun, Li Ning, Mi Yan-Jun, Yu Xiu-Yi, Luo Xian-Yang, Gao Jing, Luo Qi-Cong, Xie Jing-Dun, Fa Xian-En, Jiang Jie
Department of Thoracic Surgery, The Second Affiliated Hospital, Zhengzhou University Zhengzhou, China ; Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen University Xiamen, China.
Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen University Xiamen, China.
Int J Clin Exp Pathol. 2015 Jan 1;8(1):423-31. eCollection 2015.
SATB2, a member of the family of special AT-rich binding proteins, has been shown to affect numerous tumorigenesis. However, the role of SATB2 in esophageal squamous cell carcinoma (ESCC) remains unclear. In this study, the SATB2 expression was examined at mRNA and protein levels by quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR), Western blotting, and immunohistochemistry in ESCC tissues and adjacent non-cancerous tissues. Statistical analyses were applied to test the associations between SATB2 expression, clinicopathologic factors, and prognosis. Western blotting and qRT-PCR showed that the expression levels of SATB2 mRNA and protein were both significantly lower in SATB2 tissues than those in non-cancerous tissues. Immunohistochemistry analysis showed that SATB2 expression was significantly correlated with clinical stage and Histological differentiation. The results of Kaplan-Meier analysis indicated that a low expression level of SATB2 resulted in a significantly poor prognosis of ESCC patients. Importantly, multivariate analysis showed that low SATB2 expression was an independent prognostic factor for ESCC patients. In sum, our data suggest that SATB2 plays an important role in ESCC progression, and that decreased expression of SATB2 in tumor tissues could be used as a potential prognostic marker for patients with ESCC.
SATB2是富含AT序列结合蛋白家族的成员之一，已被证明会影响多种肿瘤的发生。然而，SATB2在食管鳞状细胞癌（ESCC）中的作用仍不清楚。在本研究中，通过定量实时逆转录聚合酶链反应（qRT-PCR）、蛋白质印迹法和免疫组织化学，在ESCC组织和癌旁非癌组织中检测了SATB2在mRNA和蛋白质水平的表达。应用统计学分析来检验SATB2表达、临床病理因素和预后之间的关联。蛋白质印迹法和qRT-PCR结果显示，SATB2组织中SATB2 mRNA和蛋白质的表达水平均显著低于非癌组织。免疫组织化学分析表明，SATB2表达与临床分期和组织学分化显著相关。Kaplan-Meier分析结果表明，SATB2低表达导致ESCC患者预后明显较差。重要的是，多因素分析显示，SATB2低表达是ESCC患者的独立预后因素。总之，我们的数据表明SATB2在ESCC进展中起重要作用，肿瘤组织中SATB2表达降低可作为ESCC患者潜在的预后标志物。
